Hep 3B2.1-7Homo sapiens (Human)Cancer cell line
Also known as: Hep 3B2_1-7, Hep 3B 2.1-7, HEP3B217, Hep 3B2, HEP-3B2, HEP3B2, Hep-3B, HEP-3B, Hep 3B, Hep3B, HEP3B, Hep_3B1_1-7
Quick Overview
Human hepatocellular carcinoma cell line with HBV surface antigen production.
Detailed Summary
Research Applications
Key Characteristics
Basic Information
| Database ID | CVCL_0326 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Liver[UBERON:UBERON_0002107] |
Donor Information
| Age | 8 |
|---|---|
| Age Category | Pediatric |
| Sex | Male |
| Race | black_or_african_american |
Disease Information
| Disease | Childhood hepatocellular carcinoma |
|---|---|
| Lineage | Liver |
| Subtype | Hepatocellular Carcinoma |
| OncoTree Code | HCC |
DepMap Information
| Source Type | ATCC |
|---|---|
| Source ID | ACH-000625_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | AXIN1 | p.Arg146Ter (c.436C>T) | Homozygous | - | from parent cell line Hep 3B2.1-7 |
| MutationSimple | RB1 | p.Ser576Ter (c.1727C>G) | Homozygous | - | from parent cell line Hep 3B2.1-7 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Screening human cell lines for viral infections applying RNA-Seq data analysis.
Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.
PLoS ONE 14:E0210404-E0210404(2019).
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
The cancer SENESCopedia: a delineation of cancer cell senescence.";
Leite de Oliveira R., Wessels L.F.A., Bernards R.
Cell Rep. 36:109441.1-109441.22(2021).
RNA sequencing of hepatobiliary cancer cell lines: data and applications to mutational and transcriptomic profiling.
Umu S.U., Rounge T.B., Roessler S., Lorenzo-Bermejo J.
Cancers (Basel) 12:2510.1-2510.14(2020).
Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
Sellers W.R., Gygi S.P.
Cell 180:387-402.e16(2020).
Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.
van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.
Nat. Commun. 10:3574.1-3574.11(2019).
A pharmacogenomic landscape in human liver cancers.";
Hui L.-J.
Cancer Cell 36:179-193.e11(2019).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
Analysis of liver cancer cell lines identifies agents with likely efficacy against hepatocellular carcinoma and markers of response.
Couchy G., Calderaro J., Nault J.-C., Zucman-Rossi J., Rebouissou S.
Gastroenterology 157:760-776(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Human hepatoma cell lines.";
Alexander J.J.
(In book chapter) Neoplasms of the liver; Okuda K., Ishak K.G. (eds.); pp.47-56; Springer; Tokyo; Japan (1987).
The p53 gene status and other cellular characteristics of human cell lines maintained in our laboratory.
Ohashi R., Namba M.
Tissue Cult. Res. Commun. 16:173-178(1997).
Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line.
Aden D.P., Fogel A., Plotkin S.A., Damjanov I., Knowles B.B.
Nature 282:615-616(1979).
Purification of alpha 1-microglobulin produced by human hepatoma cell lines. Biochemical characterization and comparison with alpha 1-microglobulin synthesized by human hepatocytes.
Revillard J.-P.
Eur. J. Biochem. 165:699-704(1987).
Comparative expression of hepatitis B virus antigens in several cell model systems.
Aspinall S., Alexander J.J., Bos P.
J. Gen. Virol. 67:2315-2323(1986).
Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen.
Knowles B.B., Howe C.C., Aden D.P.
Science 209:497-499(1980).
Detection of hepatitis B virus-specific DNA in the genomes of human hepatocellular carcinoma and liver cirrhosis tissues.
Koshy R., Maupas P., Muller R., Hofschneider P.H.
J. Gen. Virol. 57:95-102(1981).
Chromosomes of human hepatoma cell lines.";
Simon D., Aden D.P., Knowles B.B.
Int. J. Cancer 30:27-33(1982).
Mutations and altered expression of p16INK4 in human cancer.";
Harris C.C.
Proc. Natl. Acad. Sci. U.S.A. 91:11045-11049(1994).
HLA expression in hepatocellular carcinoma cell lines.";
Wadee A.A., Paterson A., Coplan K.A., Reddy S.G.
Clin. Exp. Immunol. 97:328-333(1994).
Retinoblastoma and p53 tumor suppressor genes in human hepatoma cell lines.
Ponchel F., Yakicier C., Ji J.-W., Ozturk M.
FASEB J. 7:1407-1413(1993).
p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines.
Harris C.C.
Carcinogenesis 14:987-992(1993).
Persistence of hepatitis C virus RNA in established human hepatocellular carcinoma cell lines.
Kosaka T., Tsuji T., Namba M.
J. Med. Virol. 48:133-140(1996).
Screening the p53 status of human cell lines using a yeast functional assay.
Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.
Mol. Carcinog. 19:243-253(1997).
Yeast functional assay of the p53 gene status in human cell lines maintained in our laboratory.
Fukaya K.-i., Ishioka C., Namba M.
Acta Med. Okayama 51:261-265(1997).
Yeast functional assay of the p53 gene status in 11 cell lines and 26 surgical specimens of human hepatocellular carcinoma.
Gao C., Ohashi R., Pu H., Inoue Y., Tsuji T., Miyazaki M., Namba M.
Oncol. Rep. 6:1267-1271(1999).
A comprehensive karyotypic study on human hepatocellular carcinoma by spectral karyotyping.
Wong N., Lai P.B.-S., Pang E., Leung T.W.-T., Lau J.W.-Y., Johnson P.J.
Hepatology 32:1060-1068(2000).
TFDP1, CUL4A, and CDC16 identified as targets for amplification at 13q34 in hepatocellular carcinomas.
Inazawa J.
Hepatology 35:1476-1484(2002).
Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays.
Yamori T.
Mol. Cancer Ther. 4:399-412(2005).
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Haber D.A.
Cancer Res. 70:2158-2164(2010).
Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in human and other primate cell lines.
Uphoff C.C., Denkmann S.A., Steube K.G., Drexler H.G.
J. Biomed. Biotechnol. 2010:904767.1-904767.23(2010).
Characterization of HuH6, Hep3B, HepG2 and HLE liver cancer cell lines by WNT/beta-catenin pathway, microRNA expression and protein expression profile.
Macino G., Tanzarella C., Taruscio D.
Cell. Mol. Biol. 56:OL1299-OL1317(2010).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma.
Xu J.-C.
Hepatology 58:706-717(2013).
High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions.
Laurent C., Laurent A., Cherqui D., Balabaud C., Zucman-Rossi J.
Nat. Commun. 4:2218.1-2218.7(2013).
Genetic characteristics of the human hepatic stellate cell line LX-2.";
Arnold N., Siebert R., Xu L.-M., Friedman S.L., Bergmann C.
PLoS ONE 8:E75692-E75692(2013).
Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.
Cevik D., Yildiz G., Ozturk M.
World J. Gastroenterol. 21:311-317(2015).
A resource for cell line authentication, annotation and quality control.
Neve R.M.
Nature 520:307-311(2015).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
Characterization of human cancer cell lines by reverse-phase protein arrays.
Liang H.
Cancer Cell 31:225-239(2017).